Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beckley Psytech
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.
ARM counts $14.1bn in fundraising in the first half of 2021, up 35% from mid-year 2020. Also, Chinese mRNA players Abogen raises a $700m series C venture capital round, Pfizer prices a $1bn sustainability bond and while IPOs slow in the US, China and South Korea see new first-time offerings.
The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.
- Drug Delivery